Schedule of Pharmaceutical Benefits for Approved Pharmacists and Medical Practitioners

577 Pages·2006·4.37 MB·English

by  John Abrams

SCHEDULE OF PHARMACEUTICAL
BENEFITS FOR APPROVED
PHARMACISTS AND MEDICAL
PRACTITIONERS
OPERATIVE FROM 1 APRIL 2006
(ALL PREVIOUS EDITIONS CANCELLED)
2 
© Commonwealth of Australia 2006
ISSN 1037­3667
This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part
may be reproduced by any process without prior written permission from the Commonwealth.
Requests and inquiries concerning reproduction and rights should be addressed to the
Commonwealth Copyright Administration, Attorney General’s Department, Robert Garran Offices,
National Circuit, Barton ACT 2600 or posted at http://www.ag.gov.au/cca
This Schedule provides information on the arrangements for the prescribing of
pharmaceutical benefits by medical practitioners and participating dental practitioners,
and the supply of pharmaceutical benefits by approved pharmacists, approved medical
practitioners and approved hospital authorities. These arrangements operate under the
National Health Act 1953. However, at the time of printing, the relevant legislation
giving authority for the changes included in this issue of the Schedule may still be
subject to the usual Parliamentary scrutiny. This book is not a legal document, and, in
cases of discrepancy, the legislation will be the source document for payment for the
supply of pharmaceutical benefits.
3 
CONTENTS 
Page  Page 
SUMMARY OF CHANGES...............................................5  Repeat authorisations.......................................................38 
ADDRESSES — MEDICARE AUSTRALIA...................15  Preparing repeat authorisation forms.................38 
AUTHORITY PRESCRIPTION APPLICATIONS...........16  Repeat authorisations for deferred supply..........38 
REQUESTS FOR DRUGS VIA THE SPECIAL  Authority PBS prescriptions.......................................39 
ACCESS SCHEME (SAS)........................................16  Urgent cases..............................................................39 
POISONS INFORMATION CENTRES...........................17  Receipts......................................................................39 
DRUG INFORMATION CENTRES.................................17  Emergency drug (doctor's bag) supplies...................39 
LIST OF CONTACT OFFICERS FOR RECALLS OF 
THERAPEUTIC GOODS ..........................................18  4.  PATIENT CHARGES.................................................40 
INDEX OF MANUFACTURERS' CODES.......................19  Type of patient............................................................40 
Establishing entitlement.............................................40 
What to charge...........................................................41 
SECTION 1 — EXPLANATORY NOTES —  Patient contribution..............................................41 
YELLOW PAGES  Patient contributions for early supply of some 
PBS medicines..............................................41 
INTRODUCTION..............................................................29  Special patient contributions, brand premiums 
and therapeutic group premiums..................42 
1.  THE SCHEDULE — WHERE TO FIND WHAT........29  Increased quantities............................................42 
Section 1 (yellow pages)...........................................29  Regulation 24.......................................................42 
Section 2 (white, lavender, pink and orange pages) 29  After hours...........................................................42 
Section 3 (blue pages)...............................................30  Delivery................................................................42 
Section 4 (green pages)............................................30 
Repatriation Schedule of Pharmaceutical Benefits..30  5.  THE SAFETY NET SCHEME....................................43 
Safety net thresholds.................................................43 
2.  PRESCRIBING MEDICINES — INFORMATION  Safety net cross­over arrangements...................44 
FOR DOCTORS AND DENTISTS............................30  Recording PBS prescriptions.....................................44 
Eligible prescribers....................................................30  Hospital PRF's............................................................45 
PBS prescription forms..............................................30  Multi­item forms..........................................................45 
Ordering forms....................................................31  Qualifying PBS prescriptions.....................................45 
Preparing general PBS prescriptions........................31  Lost PRF's..................................................................45 
Do's and don't's...................................................31  Retrospective entitlement and patient refunds .........46 
Writing the PBS prescription...............................32  Applying for a Safety Net Entitlement/Concession 
Restrictions................................................................33  Card .....................................................................46 
Authority PBS prescriptions ......................................33  Issuing a Safety Net Entitlement/Concession Card..47 
Writing authority PBS prescriptions....................33  Issuing supplementary cards.....................................47 
Maximum quantities and repeats..............................34  Notification to Medicare Australia and 
Regulation 24.............................................................35  claim for payment................................................47 
Urgent cases..............................................................35  Lost Safety Net Entitlement/Concession Cards........47 
Drugs of addiction......................................................35  Pharmacy record of issued cards..............................47 
Emergency drug (doctor's bag) supplies..................35 
6.  MEDICARE AUSTRALIA ENTITLEMENT CHECKS48 
3.  SUPPLYING MEDICINES — WHAT  General................................................................48 
PHARMACISTS NEED TO KNOW...........................36  Concessional.......................................................48 
Eligible suppliers........................................................36  Entitlement checking procedures..............................48 
Approval conditions for pharmacists..................36  General................................................................48 
Before supplying pharmaceutical benefits................36  Concessional.......................................................48 
Supplying pharmaceutical benefits...........................37  Step by step.........................................................49
Do's and don't's...................................................37 
What to do if the Schedule changes...................37 
Suspected forgery......................................................38 
Regulation 24.............................................................38
4 
Page  Page 
7.  HOW PHARMACISTS CLAIM REIMBURSEMENT:  SECTION 2 — READY­PREPARED 
INFORMATION REQUIRED.....................................49  PHARMACEUTICAL BENEFITS — 
PBS prescription identification ..................................49  WHITE, LAVENDER, PINK AND ORANGE PAGES65 
Serial numbers...........................................................50  Symbols......................................................................66 
Repeat authorisations for authority  Emergency Drug (Doctor's Bag) Supplies ................69 
PBS prescriptions........................................50  Special Pharmaceutical Benefits...............................72 
Repeat authorisations for deferred supply.........50  General Pharmaceutical Benefits .............................76 
Dropper containers....................................................50  Pharmaceutical Benefits for Palliative Care ...........319 
Extemporaneously­prepared pharmaceutical  Pharmaceutical Benefits for Dental Use.................333 
benefits not included in the Standard Formulae  Items Available under Special Arrangements 
List.......................................................................50  (section 100)......................................................357 
PBS prescriptions paid on an average price 
basis..............................................................51  SECTION 3 — STANDARD PACKS AND PRICES — 
Pricing non­pre­priced extemporaneous  BLUE PAGES..........................................................433 
preparations..................................................51  Container Prices and Fees for Ready Prepared 
RPBS prescriptions for items not included in either  Pharmaceutical Benefits....................................433 
the PBS or RPBS Schedule................................51  Standard Packs and Prices for Ready Prepared 
Pharmaceutical Benefits....................................434 
8.  HOW PHARMACISTS CLAIM REIMBURSEMENT: 
DOCUMENTS TO BE SUBMITTED.........................51  SECTION 4 — EXTEMPORANEOUSLY­PREPARED 
Completing the claim form.........................................52  PHARMACEUTICAL BENEFITS — 
Lodging claims...........................................................52  GREEN PAGES.......................................................447 
Reconciliation statements .........................................52  Drug Tariff.................................................................448 
Container Prices.......................................................452 
9.  PRICING PBS PRESCRIPTIONS.............................53  Standard Formula Preparations..............................453 
Pricing principles........................................................53  Table of Codes, Maximum Quantities and Number 
Pricing dates..............................................................53  of Repeats for Extemporaneously Prepared 
Pricing ready­prepared items....................................53  Pharmaceutical Benefits....................................455 
For maximum quantities......................................53 
For lesser quantities............................................53  REPATRIATION PHARMACEUTICAL BENEFITS — 
Wastage table percentage ........................................54  WHITE, MAUVE AND BUFF PAGES.....................457 
Pricing extemporaneously­prepared items...............54  Beneficiaries' Entitlement Cards..............................458 
General................................................................54  Explanatory Notes....................................................460 
Pricing of ingredients...........................................55  Summary of Changes..............................................465 
Pricing PBS prescriptions where extra  Therapeutic Index....................................................467 
ingredients are added to a formula..............55  SECTION 1 — Drugs, Medicines and Dressings...471 
Containers...........................................................55  SECTION 2 — Standard Packs and Prices............513 
Special provisions for extemporaneous 
PBS prescriptions outside the Standard  GENERIC/PROPRIETARY INDEX — 
Formulae List................................................55  MAUVE PAGES.......................................................517
10. MISCELLANEOUS....................................................56 
References.................................................................56 
Standards ..................................................................56 
Legislation..................................................................56 
THERAPEUTIC INDEX — MAUVE PAGES ..................57
5 
PHARMACEUTICAL BENEFITS
This Schedule will take effect on 1 April 2006 and all previous issues are cancelled.
New Schedules will take effect on 1 April, 1 August and 1 December each year.
Change of Address
Notification of change of address should be directed to the Pharmaceutical Branch, Medicare
Australia, GPO Box 9826, in your Capital City, or telephone 132 290.
Internet
The Schedule of Pharmaceutical Benefits is also available on the Department of Health and
Ageing’s internet site at www.health.gov.au.
The address of the Schedule is http://www.health.gov.au/pbschedule
Fees, Patient Contributions and Safety Net Thresholds
The following fees, patient contributions and safety net thresholds apply as at 1 April 2006 and
are included, where applicable, in prices published in the Schedule—
Dispensing Fees: Ready­prepared $4.94
Dangerous drug fee $2.61
Extemporaneously­prepared $6.97
Additional Fees (for safety net prices): Ready­prepared $0.97
Extemporaneously­prepared $1.38
Patient Co­payments: General $29.50
Concessional $4.70
Safety Net Thresholds: General $960.10
Concessional $253.80
Safety Net Card Issue Fee: $7.43
SUMMARY OF CHANGES
ADDITIONS
Additions — Items
8889W Candesartan Cilexetil, tablet 32 mg (Atacand)
8898H Carmustine, implants 7.7 mg, 8 (Gliadel)
8879H Eplerenone, tablet 25 mg (Inspra) (effective 1 February 2006)
8880J Eplerenone, tablet 50 mg (Inspra) (effective 1 February 2006)
8886Q Esomeprazole Magnesium Trihydrate, tablet (enteric coated), equivalent to 20 mg
esomeprazole (Nexium)
8881K Ezetimibe with Simvastatin, tablet 10 mg­40 mg (Vytorin) (effective 1 February 2006)
8882L Ezetimibe with Simvastatin, tablet 10 mg­80 mg (Vytorin) (effective 1 February 2006)
8897G Famciclovir, tablet 500 mg (Famvir)
8896F Famciclovir, tablet 500 mg (Famvir) (Diff. Max. Qty and Rpts)
6 
8878G Fentanyl, transdermal patch, 2.1 mg (releasing approximately 12 micrograms per hour)
(Durogesic 12) (effective 1 February 2006)
8891Y Fentanyl, transdermal patch 4.2 mg (releasing approximately 25 micrograms per hour)
(Durogesic 25)
8892B Fentanyl, transdermal patch 8.4 mg (releasing approximately 50 micrograms per hour)
(Durogesic 50)
8893C Fentanyl, transdermal patch 12.6 mg (releasing approximately 75 micrograms per hour)
(Durogesic 75)
8894D Fentanyl, transdermal patch 16.8 mg (releasing approximately 100 micrograms per
hour) (Durogesic 100)
8890X Glucose Indicator—Blood, electrode strips, 50 (Freestyle Papillon)
8874C Insulin Lispro—Insulin Lispro Protamine Suspension, injections (human analogue)
100 units (50 units–50 units) per mL, 3 mL, 5 (Humalog Mix50)
(effective 1 January 2006)
8895E Latanoprost with Timolol Maleate, eye drops 50 micrograms­5 mg (base) per mL
(0.005%­0.5%), 2.5 mL (Xalacom)
8875D Leuprorelin Acetate, I.M. injection (modified release), powder for injection 7.5 mg with
diluent in pre­filled dual­chamber syringe (Lucrin Depot 7.5mg PDS)
(effective 1 February 2006)
8876E Leuprorelin Acetate, I.M. injection (modified release), powder for injection 22.5 mg with
diluent in pre­filled dual­chamber syringe (Lucrin Depot 3 Month PDS)
(effective 1 February 2006)
8877F Leuprorelin Acetate, I.M. injection (modified release), powder for injection 30 mg with
diluent in pre­filled dual­chamber syringe (Lucrin Depot 4 Month PDS)
(effective 1 February 2006)
8887R Meloxicam, capsule 7.5 mg (Mobic)
8888T Meloxicam, capsule 15 mg (Mobic)
8884N Metformin Hydrochloride, tablet 500 mg (extended release) (Diabex XR)
8883M Mirtazapine, tablet 45 mg (Avanza, Mirtazon)
1658G Naproxen, oral suspension 125 mg per 5 mL, 474 mL (Naprosyn)
8899J Risedronate Sodium and Calcium Carbonate, pack containing 4 tablets risedronate
sodium 35 mg and 24 tablets calcium carbonate 1.25 g (equivalent to 500 mg
calcium) (Actonel Combi)
8885P Sumatriptan Succinate, tablet 50 mg (base) (fast disintegrating) (Imigran FDT)
Additions—PBS Authority Required Special Patient Contribution Exemption Codes
A special patient contribution now applies to Lansoprazole, sachet containing granules for oral
suspension, 30 mg per sachet (see Special Pharmaceutical Benefits section in the Schedule). The
following codes have been established to provide for cases where an authority has been obtained
that grants exemption from the special patient contribution:
9730D Lansoprazole, sachet containing granules for oral suspension, 30 mg per sachet (Zoton)
9731E Lansoprazole, sachet containing granules for oral suspension, 30 mg per sachet (Zoton)
(Diff. Max. Rpts)
Additions — Brands
8465M Bupropion­RL, RE; Clorprax, HX — Bupropion Hydrochloride, tablet 150 mg
(sustained release)
8710K Bupropion­RL, RE; Clorprax, HX — Bupropion Hydrochloride, tablet 150 mg
(sustained release) (Diff. Max. Qty)
7 
8740B Calcium Folinate Ebewe, IT — Calcium Folinate, injection equivalent to 50 mg folinic
acid in 5 mL
8812T Calcium Folinate Ebewe, IT — Calcium Folinate, injection equivalent to 100 mg folinic
acid in 10 mL
1209P GN — Ciprofloxacin, tablet 500 mg
1210Q GN — Ciprofloxacin, tablet 750 mg
3196F restore O.R.S., DP — Electrolyte Replacement (Oral), sachets containing powder for
oral solution 4.9 g, 10
8505P DBL Gabapentin, MX — Gabapentin, capsule 100 mg
8450R Diapride 1, AW — Glimepiride, tablet 1 mg
8451T Diapride 2, AW — Glimepiride, tablet 2 mg
8533D Diapride 3, AW — Glimepiride, tablet 3 mg
8452W Diapride 4, AW — Glimepiride, tablet 4 mg
2430X GN — Metformin Hydrochloride, tablet 500 mg
1801T GN — Metformin Hydrochloride, tablet 850 mg
1929M MX — Mitozantrone Hydrochloride, injection 20 mg (base) in 10 mL
8331L Omepral, PM — Omeprazole, tablet 20 mg
8333N Omepral, PM — Omeprazole, tablet 20 mg (Diff. Max. Rpts)
8224W Ondansetron­RL, RE; Ondaz, HX — Ondansetron, tablet 4 mg
1594X Ondansetron­RL, RE; Ondaz, HX — Ondansetron, tablet 4 mg (Diff. Max. Qty and Rpts)
8225X Ondansetron­RL, RE; Ondaz, HX — Ondansetron, tablet 8 mg
1595Y Ondansetron­RL, RE; Ondaz, HX — Ondansetron, tablet 8 mg (Diff. Max. Qty and Rpts)
8410P Ondansetron­RL Zydis, RE; Ondaz Zydis, HX — Ondansetron, wafer 4 mg
8412R Ondansetron­RL Zydis, RE; Ondaz Zydis, HX — Ondansetron, wafer 4 mg
(Diff. Max. Qty and Rpts)
8411Q Ondansetron­RL Zydis, RE; Ondaz Zydis, HX — Ondansetron, wafer 8 mg
8413T Ondansetron­RL Zydis, RE; Ondaz Zydis, HX — Ondansetron, wafer 8 mg
(Diff. Max. Qty and Rpts)
8226Y Ondansetron­RL, RE; Ondaz, HX — Ondansetron, I.V. injection 4 mg in 2 mL
1596B Ondansetron­RL, RE; Ondaz, HX — Ondansetron, I.V. injection 4 mg in 2 mL
(Diff. Restriction)
8227B Ondansetron­RL, RE; Ondaz, HX — Ondansetron, I.V. injection 8 mg in 4 mL
1597C Ondansetron­RL, RE; Ondaz, HX — Ondansetron, I.V. injection 8 mg in 4 mL
(Diff. Restriction)
3017T Taxol, BQ — Paclitaxel, solution concentrate for I.V. infusion 150 mg in 25 mL
1746X Chem mart Chemadol, CH — Paracetamol, tablet 500 mg
5196L Chem mart Chemadol, CH — Paracetamol, tablet 500 mg (Dental)
8784H Chem mart Chemadol, CH — Paracetamol, tablet 500 g (Diff. Max. Qty and Rpts)
5224Y Chem mart Chemadol, CH — Paracetamol, tablet 500 g (Diff. Max. Qty)
(Dental)
1760P Roxar 150, AW; Roximycin, AF — Roxithromycin, tablet 150 mg
8016X Roxar 300, AW; Roximycin, AF — Roxithromycin, tablet 300 mg
2011W GN — Simvastatin, tablet 10 mg
2012X GN — Simvastatin, tablet 20 mg
8173E GN — Simvastatin, tablet 40 mg
8313M GN — Simvastatin, tablet 80 mg
8455B Tramedo, AF — Tramadol Hydrochloride, capsule 50 mg
8611F Tramedo, AF — Tramadol Hydrochloride, capsule 50 mg (Diff. Max. Rpts)
5232J Tramedo, AF — Tramadol Hydrochloride, capsule 50 mg (Dental)
8582Q Tramahexal, HX — Tramadol Hydrochloride, injection 100 mg in 2 mL
5231H Tramahexal, HX — Tramadol Hydrochloride, injection 100 mg in 2 mL (Dental)
3484J Tramahexal, HX — Tramadol Hydrochloride, injection 100 mg in 2 mL (Doctor’s Bag)
8 
RETENTION OF ITEM
Contrary to previous advice, the following item will continue to be available as a pharmaceutical
benefit from 1 April 2006:
2418G Amitriptyline Hydrochloride, tablet 25 mg (Tryptanol)
BIOEQUIVALENCE INDICATORS
The bioequivalence indicator (a) has been added to the following brands:
8812T Leucovorin Calcium, PF — Calcium Folinate, injection equivalent to 100 mg folinic acid
in 10 mL
3196F Repalyte New Formulation, AV — Electrolyte Replacement (Oral), sachets containing
powder for oral solution 4.9 g, 10
8023G Lescol, NV; Vastin, NM — Fluvastatin Sodium, capsule 20 mg (fluvastatin)
8024H Lescol,NV; Vastin, NM — Fluvastatin Sodum, capsule 40 mg (fluvastatin)
8224W Zofran, GK — Ondansetron, tablet 4 mg
1594X Zofran, GK — Ondansetron, tablet 4 mg (Diff. Max. Qty and Rpts)
8225X Zofran, GK — Ondansetron, tablet 8 mg
1595Y Zofran, GK — Ondansetron, tablet 8 mg (Diff. Max. Qty and Rpts)
8410P Zofran Zydis, GK — Ondansetron, wafer 4 mg
8412R Zofran Zydis, GK — Ondansetron, wafer 4 mg (Diff. Max. Qty and Rpts)
8411Q Zofran Zydis, GK — Ondansetron, wafer 8 mg
8413T Zofran Zydis, GK — Ondansetron, wafer 8 mg (Diff. Max. Qty and Rpts)
8226Y Zofran, GK — Ondansetron, I.V. injection 4 mg in 2 mL
1596B Zofran, GK — Ondansetron, I.V. injection 4 mg in 2 mL (Diff. Restriction)
8227B Zofran, GK — Ondansetron, I.V. injection 8 mg in 4 mL
1597C Zofran, GK — Ondansetron, I.V. injection 8 mg in 4 mL (Diff. Restriction)
2013Y Lipex 5, FR — Simvastatin, tablet 5 mg
8582Q Tramal 100, CS — Tramadol Hydrochloride, injection 100 mg in 2 mL
5231H Tramal 100, CS — Tramadol Hydrochloride, injection 100 mg in 2 mL (Dental)
3484J Tramal 100, CS — Tramadol Hydrochloride, injection 100 mg in 2 mL (Doctor’s Bag)
DELETIONS
Deletions — Items
1029E Alteplase, injection set containing 1 vial 50 mg in 2333 mg dry powder, 1 vial sterile
water for injection 50 mL and 1 transfer cannula (Actilyse)
2535K Carbachol, eye drops 15 mg per mL (1.5%), 15 mL (Isopto Carbachol)
2536L Carbachol, eye drops 30 mg per mL (3%), 15 mL (Isopto Carbachol)
1319K Diflunisal, tablet 250 mg (Dolobid)
5080J Diflunisal, tablet 250 mg (Dolobid) (Dental)
1320L Diflunisal, tablet 500 mg (Dolobid)
5081K Diflunisal, tablet 500 mg (Dolobid) (Dental)
1809F Fluoxetine Hydrochloride, oral solution 20 mg (base) per 5 mL, 140mL (Lovan Liquid)
8437C Follitropin Beta, solution for injection 100 i.u. in 0.5 mL ( Puregon 100 IU/0.5 mL)
8438D Follitropin Beta, solution for injection 150 i.u. in 0.5 mL ( Puregon 150 IU/0.5 mL)
8835B Follitropin Beta, solution for injection 200 i.u. in 0.5 mL ( Puregon 200 IU/0.5 mL)
8053W Glucose Indicator—Blood, reagent strips, 50 (Betachek­MERIDIAN)
9 
2542T Homatropine Hydrobromide, eye drops 50 mg per mL (5%), 15 mL
(Isopto Homatropine)
1489J Hydrocortisone, eye drops 5 mg per mL (0.5%), 10 mL (Hycor)
1492M Hydrocortisone, eye drops 10 mg per mL (1%), 10 mL (Hycor)
1061W Oestradiol Valerate, injection 10 mg in 1 mL (Primogyn Depot)
8539K Oxaliplatin, powder for I.V. infusion 50 mg (Eloxatin)
8540L Oxaliplatin, powder for I.V. infusion 100 mg (Eloxatin)
1828F Pethidine Hydrochloride, injection 50 mg in 1 mL (MX)
5199P Pethidine Hydrochloride, injection 50 mg in 1 mL (MX) (Dental)
3483H Pethidine Hydrochloride, injection 100 mg in 2 mL (MX) (Doctor’s Bag)
8813W Tetanus Vaccine, Absorbed, injection 0.5 mL in pre­filled syringe (Tet­Tox)
5251J Tetanus Vaccine, Absorbed, injection 0.5 mL in pre­filled syringe (Tet­Tox) (Dental)
3492T Tetanus Vaccine, Absorbed, injection 0.5 mL in pre­filled syringe (Tet­Tox)
(Doctor’s Bag)
1143E Theophylline, tablet 125 mg (Nuelin)
8068P Venlafaxine Hydrochloride, tablet 37.5 mg (base) (Efexor)
8069Q Venlafaxine Hydrochloride, tablet 75 mg (base) (Efexor)
Deletions — Brands
1007B Zyclir 200, AW — Aciclovir, tablet 200 mg
1052J Zyclir 800, AW — Aciclovir, tablet 800 mg
1157X Cimehexal, HX — Cimetidine, tablet 200 mg
1158Y Cimehexal, HX — Cimetidine, tablet 400 mg
1159B Cimehexal, HX — Cimetidine, tablet 800 mg
1459T Nitrostat, LM — Glyceryl Trinitrate, tablets 600 micrograms, 100
5108W Nitrostat, LM — Glyceryl Trinitrate, tablets 600 micrograms, 100 (Dental)
1558B Arsorb 60, AW — Isosorbide Mononitrate, tablet 60 mg (sustained release)
2591J Isohexal, HX — Isotretinoin, capsule 10 mg
1622J Ledertrexate, WY — Methotrexate, tablet 2.5 mg
1644M SI — Morphine Sulfate, injection 10 mg in 1 mL
5168B SI — Morphine Sulfate, injection 10 mg in 1 mL (Dental)
1645N SI — Morphine Sulfate, injection 15 mg in 1 mL
5169C SI — Morphine Sulfate, injection 15 mg in 1 mL (Dental)
3479D SI — Morphine Sulfate, injection 15 mg in 1 mL (Doctor’s Bag)
3010K Insensye, FR — Norfloxacin, tablet 400 mg
2597Q Isopto Carpine, AQ — Pilocarpine Hydrochloride, eye drops 30 mg per mL (3%), 15 mL
2109B Tamoxifen Hexal, HX — Tamoxifen Citrate, tablet 10 mg (base)
1248Q Verahexal, HX — Verapamil Hydrochloride, tablet 40 mg
1250T Verahexal, HX — Verapamil Hydrochloride, tablet 80 mg
1254B Verahexal, HX — Verapamil Hydrochloride, tablet 120 mg
ALTERATIONS
Restriction Changes
The following items have changed from “restricted benefit” to “unrestricted”:
2339D Spironolactone, tablet 25 mg (Spiractin 25, Aldactone)
2340E Spironolactone, tablet 100 mg (Spiractin 100, Aldactone)
10 
Other restriction changes:
8511Y Alendronate Sodium, tablet equivalent to 70 mg alendronic acid (Alendro Once Weekly,
Fosamax Once Weekly)
8845M Balsalazide Sodium, capsule 750 mg (Colazide)
8361C Capecitabine, tablet 150 mg (Xeloda)
8362D Capecitabine, tablet 500 mg (Xeloda)
8657P Cyclosporin, capsule 10 mg (Neoral 10)
8658Q Cyclosporin, capsule 25 mg (Cicloral, Cysporin, Neoral 25)
8659R Cyclosporin, capsule 50 mg (Cicloral, Cysporin, Neoral 50)
8660T Cyclosporin, capsule 100 mg (Cicloral, Cysporin, Neoral 100)
8661W Cyclosporin, oral liquid 100 mg per mL, 50 mL (Neoral)
8056B Disodium Etidronate and Calcium Carbonate, pack containing 28 tablets disodium
etidronate 200 mg and 76 tablets calcium carbonate 1.25 g (equivalent to 500 mg
calcium) (Didrocal)
8757X Ezetimibe, tablet 10 mg (Ezetrol) (effective 1 February 2006)
1611T Mesalazine, tablet 250 mg (Mesasal)
8731M Mesalazine, tablet 500 mg (enteric coated) (Salofalk)
8598M Mesalazine, sachet containing granules, 500 mg per sachet (Salofalk)
8599N Mesalazine, sachet containing granules, 1 g per sachet (Salofalk)
8753Q Mesalazine, enemas 1 g in 100 mL, 7 (Pentasa)
8816B Modafinil, tablet 100 mg (Modavigil)
8363E Raloxifene Hydrochloride, tablet 60 mg (Evista)
8481J Risedronate Sodium, tablet 5 mg (Actonel)
8621R Risedronate Sodium, tablet 35 mg (Actonel Once­a­Week)
3169T Risperidone, tablet 1 mg (Risperdal)
8792R Risperidone, tablet 1 mg (orally disintegrating) (Risperdal Quicklet)
3170W Risperidone, tablet 2 mg (Risperdal)
8794W Risperidone, tablet 2 mg (orally disintegrating) (Risperdal Quicklet)
3171X Risperidone, tablet 3 mg (Risperdal)
3172Y Risperidone, tablet 4 mg (Risperdal)
8100H Risperidone, oral solution 1 mg per mL, 100 mL (Risperdal)
Alterations — Notes
Notes have been added in respect of the following:
Capecitabine
Temozolomide
Notes have been amended in respect of the following:
Buprenorphine
Hydromorphone Hydrochloride
Methadone Hydrochloride
Morphine Hydrochloride
Morphine Sulfate
Oxycodone
Oxycodone Hydrochloride